# Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

> **NCT03736837** · PHASE2 · COMPLETED · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 60 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Anlotinib Plus Icotinib

## Key facts

- **NCT ID:** NCT03736837
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-01
- **Primary completion:** 2021-01-01
- **Final completion:** 2021-01-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-03-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03736837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03736837, "Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03736837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*